All patients (n = 148) | Steroid (S) group (n = 47) | Steroid- history (SH) group (n = 36) | Untreated (U) group (n = 32) | Miscella- neous (M) group (n = 33) | p value | Groups with significant difference c) | |
---|---|---|---|---|---|---|---|
Sex: Female | 112 (75.7%) | 36 (76.6%) | 25 (69.4%) | 24 (75.0%) | 27 (81.8%) | 0.690 a) | – |
Age at baseline (year)d | 61.8 ± 9.7 | 63.0 ± 7.5 | 61.4 ± 9.7 | 60.6 ± 12.4 | 61.5 ± 9.7 | 0.740 b) | – |
Age at onset (year)d | 43.4 ± 14.4 | 47.5 ± 13.0 | 40.5 ± 15.2 | 42.2 ± 13.1 | 41.7 ± 15.7 | 0.113 b) | – |
Disease durationd (Time from onset to initial interview) | 17.5 ± 10.4 | 15.7 ± 9.4 | 19.8 ± 10.0 | 16.6 ± 10.6 | 18.3 ± 11.9 | 0.300 b) | – |
Baseline OMDSd | 5.8 ± 2.2 | 6.0 ± 2.3 | 6.6 ± 2.4 | 4.8 ± 1.4 | 5.7 ± 2.1 | 0.012 b) | SH > U |
Rapid progressorse | 21 (14.2%) | 10 (21.3%) | 5 (13.9%) | 3 (9.4%) | 3 (9.1%) | 0.354 a) | – |